Print This PageKarin D. Rodland, Ph.D.
Expertise
Karin Rodland
Dr. Rodland's research is focused on understanding the control of critical cellular decisions: to divide or remain quiescent; to differentiate or remain multipotent; to repair damage or die by apoptosis. Of particular interest to her is the difference in the signal transduction mechanisms regulating these processes in ovarian surface epithelial cells and in ovarian adenocarcinoma cells derived from the normal epithelial cells. Dr. Rodland was the among the first to demonstrate that variations in extracellular calcium concentration could be sensed by a variety of epithelial and mesenchymal cells through activation of the G-protein coupled calcium-sensing receptor, resulting in activation of the Ras-Raf-MEK-ERK signaling cascade. Dr. Rodland is involved in efforts to apply a proteomics-based approach to the characterization of protein-protein interactions in signaling pathways, and to the identification of differences in plasma membrane protein expression associated with various disease states, including cancer.
Experience
Prior to joining Pacific Northwest National Laboratory, Dr. Rodland was an associate professor in the department of cell and developmental biology at Oregon Health Sciences University from 1985-2001. Dr. Rodland retains her status as member of the Oregon Cancer Institute and as a collaborating scientist at the Oregon Regional Primate Research Center.
Dr. Rodland is a regular member of the Metabolic Pathology - Oncology Initial Review Group for the National Institutes of Health, and has served on several other NIH study sections, including the parent Program Project review committee and the ovarian cancer SPORE program. Dr. Rodland is also a regular reviewer for the Department of Defense Breast Cancer and Ovarian Cancer review panels, and has reviewed for the Veteran's Administration Oncology program and the California Breast Cancer Research Program. In addition, Dr. Rodland has reviewed manuscripts regularly for several publications, including Experimental Cell Research, Science, Proceedings of the National Academy of Science, Cancer Research, Journal of Clinical Investigation, Endocrinology, Journal of Neurochemistry, and the European Journal of Biochemistry.
Education
- National Cancer Institute Public Health Research
Service Award, Syracuse University, 1976-1978 - Ph.D., Biology, Syracuse University, 1974
- A.B., Biology summa cum laude, Hood College, 1970
Professional Societies
- American Society for Cell Biology
- American Society for Biochemistry and Molecular Biology
- American Association for Cancer Research
- American Association for the Advancement of Science
Patents
- Hybridization method of detecting nucleic acid sequences with probe containing thionucleotide. U.S. Patent #4647529
- Hybridization method and probe for detecting nucleic acid sequences. U.S. Patent #4908307
- Hybridization method and probe for detecting nucleic acid sequences. U.K. Patent #GB 2199946
- In vitro assays to evaluate chemotherapeutic effectiveness of drugs
Selected Publications
Rodland KD. 2004. "Proteomics and Cancer Diagnosis: The Potential of Mass Spectrometry." Clinical Biochemistry 37(7):579-583.
Rodland KD. 2004. “The Role of the Calcium-sensing Receptor in Cancer.” Cell Calcium 35(3):291-295.
Springer DL, Auberry DL, Ahram M, Adkins JN, Feldhaus JM, Wahl JH, Wunschel DS, Rodland KD. 2004. "Characterization of plasma membrane proteins from ovarian cancer cells using mass spectrometry". Disease Markers 19(4-5):219-28.
Tomlins SA, Creim J, and Rodland KD. 2005. "Cross-talk between the calcium-sensing receptor and the epidermal growth factor receptor in Rat-1 fibroblasts". Exp. Cell Res 308(2):439-445.
Adkins JN, Monroe ME, Auberry KJ, Shen Y, Jacobs JM, Camp DG II, Vitzhum F, Rodland KD, Smith RD, Pounds JG. 2005. "A proteomic study of the HUPO Plasma Proteome Project's pilot samples using an accurate mass and time tag strategy". Proteomics 5(13): p. 3454-66.
